Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 20/20 | 1.00 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.95 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.95 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393244 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL14401254 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL13038499 | 0.98 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL154547 | 0.98 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL7546702 | 0.98 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL29405867 | 0.98 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL355913 | 0.92 | FKBP1A (0.85) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL29860052 | 0.92 | FKBP1A (0.85) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL1648827 | 0.91 | FKBP1A (0.84) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL18574236 | 0.88 | FKBP1A (0.79) | FKBP1AFKBP4FKBP5ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20030103959-A1 | Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor | ENDOCRINZ LIMITED (NZ) | 2003-06-05 | — | — | US | disclosed |
| WO-2003000281-A1 | NEUROPROTECTION AND/OR NEURORESTORATION VIA THE NEURAL AVTIVIN TYPE IIB RECEPTOR | NEURONZ LIMITED (NZ) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | ICOS, CD14, MAVS | FKBP1A 1524/4885FKBP4 1853/4885FKBP5 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.